WO2008001184A3 - Solid composition - Google Patents
Solid composition Download PDFInfo
- Publication number
- WO2008001184A3 WO2008001184A3 PCT/IB2007/001722 IB2007001722W WO2008001184A3 WO 2008001184 A3 WO2008001184 A3 WO 2008001184A3 IB 2007001722 W IB2007001722 W IB 2007001722W WO 2008001184 A3 WO2008001184 A3 WO 2008001184A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solid composition
- diuretic
- ace
- inhibitor
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to an oral, stable pharmaceutical composition of angiotensin converting enzyme (ACE) inhibitor in combination with a diuretic, and to a process for preparation thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN995/MUM/2006 | 2006-06-26 | ||
| IN995MU2006 | 2006-06-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008001184A2 WO2008001184A2 (en) | 2008-01-03 |
| WO2008001184A3 true WO2008001184A3 (en) | 2008-04-17 |
Family
ID=38695581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2007/001722 Ceased WO2008001184A2 (en) | 2006-06-26 | 2007-06-22 | Solid composition |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008001184A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200906322A2 (en) | 2009-08-17 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Granules with improved solubility and stability properties. |
| ES2364011B1 (en) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | CAPSULES OF PHARMACEUTICAL ACTIVE AND ESTERS OF POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES. |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014343A1 (en) * | 2002-08-02 | 2004-02-19 | Ranbaxy Laboratories Limited | Storage stable tablets of fosinopril sodium |
| WO2005011586A2 (en) * | 2003-07-28 | 2005-02-10 | Dr. Reddy's Laboratories, Inc. | Treatment and preventi0n of cardiovascular events |
| WO2005079762A1 (en) * | 2004-02-20 | 2005-09-01 | Boehringer Ingelheim International Gmbh | Multilayer tablet |
| US20050202081A1 (en) * | 2002-01-15 | 2005-09-15 | Deepak Bahl | Stable pharmaceutical compositions comprising ace inhibitor(s) |
-
2007
- 2007-06-22 WO PCT/IB2007/001722 patent/WO2008001184A2/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050202081A1 (en) * | 2002-01-15 | 2005-09-15 | Deepak Bahl | Stable pharmaceutical compositions comprising ace inhibitor(s) |
| WO2004014343A1 (en) * | 2002-08-02 | 2004-02-19 | Ranbaxy Laboratories Limited | Storage stable tablets of fosinopril sodium |
| WO2005011586A2 (en) * | 2003-07-28 | 2005-02-10 | Dr. Reddy's Laboratories, Inc. | Treatment and preventi0n of cardiovascular events |
| WO2005079762A1 (en) * | 2004-02-20 | 2005-09-01 | Boehringer Ingelheim International Gmbh | Multilayer tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008001184A2 (en) | 2008-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006131591A3 (en) | An entacapone-containing oral dosage form | |
| WO2006091529A3 (en) | A solid pharmaceutical dosage formulation | |
| WO2008011335A3 (en) | Metal binding compounds, metal binding compositions, and their uses | |
| SG171649A1 (en) | Dpp iv inhibitor formulations | |
| WO2009149956A3 (en) | Fusion protein and use thereof | |
| WO2009082701A8 (en) | Hcv protease inhibitors and uses thereof | |
| WO2007146965A3 (en) | Compounds for the treatment of periodontal disease | |
| WO2007100901A3 (en) | Epinephrine dosing regimens | |
| WO2007095116A3 (en) | Glass compositions for protecting glass and methods of making and using thereof | |
| WO2009004629A3 (en) | A method for decreasing symptoms of alcohol consumption | |
| WO2005067893A3 (en) | Pharmaceutical compositions comprising midazolam in a high concentration | |
| WO2008083130A3 (en) | Amorphous and crystalline form a of carvedilol phosphate | |
| WO2007130822A3 (en) | Mglur5 modulators iii | |
| WO2006002348A8 (en) | Solid and crystalline ibandronic acid | |
| WO2008070257A3 (en) | Crystal structure of a trna synthetase | |
| WO2009004593A3 (en) | Processes for the preparation of epinephrine | |
| WO2008113901A3 (en) | Composition with controlled release of levetiracetam and method for preparing same | |
| WO2005067887A3 (en) | Formulations of ramipril | |
| WO2008156645A3 (en) | Pharmaceutical compositions and uses | |
| WO2007125521A3 (en) | Polymorphic form of zoledronic acid and processes for their preparation | |
| WO2007099555A3 (en) | Pharmaceutical tablet compositions containing irbesartan | |
| WO2007134845A3 (en) | Olanzapine pharmaceutical composition | |
| WO2008001184A3 (en) | Solid composition | |
| WO2007143152A3 (en) | Preparation of (s)-pregabalin-nitrile | |
| AU2008269712A8 (en) | New antithrombin function compounds and pharmaceutical compositions based on them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07766584 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| NENP | Non-entry into the national phase |
Ref country code: RU |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07766584 Country of ref document: EP Kind code of ref document: A2 |